Latest CYP2D6 Stories
Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors (SSRIs), prescribed drugs that inhibit the effect of an important enzyme.
BOSTON, March 17 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that it has completed a large and complex pharmacogenetics-based early phase study.
Among women with early stage breast cancer, genetic variation of a certain enzyme appears to be associated with clinical outcomes for women treated with tamoxifen, according to a study in the October 7 issue of JAMA.
- Several SSRIs more than double risk of cancer recurrence in tamoxifen treated patients - Nearly 30 percent of tamoxifen users take drugs that reduce its effectiveness against breast cancer ORLANDO, Fla., May 30 /PRNewswire-FirstCall/ -- An important new study finds that certain popular antidepressants frequently prescribed to women taking the breast cancer drug tamoxifen more than double the risk of a breast cancer recurrence for those using both medications.
Popular antidepressants taken with tamoxifen can increase the risk of breast cancer recurrence PHILADELPHIA, May 30 /PRNewswire-USNewswire/ -- A new study found that taking tamoxifen with certain antidepressants more than doubled the risk of breast cancer recurrence in women taking both medications.
SEATTLE, Oct. 30 /PRNewswire/ -- Nearly one third of breast cancer patients prescribed tamoxifen currently fail treatment.
By Will Boggs, MD NEW YORK (Reuters Health) - The gene for an enzyme called cytochrome P450 2D6 (CYP2D6) influences how well the breast cancer drug tamoxifen works and whether hot flashes are likely to occur, according to a report in the Journal of Clinical Oncology.